Anlotinib in Advanced Solid Tumors With FGFR Alteration

Advanced Solid Tumor Clinical Trial

Official title:

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03929965
• Other study ID #: ASTFA
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2019
• Est. completion date: July 1, 2023

Study information

• Verified date: April 2019
• Source: Shanghai Changzheng Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: July 1, 2023
• Est. primary completion date: July 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Patients should be histologically diagnosed with advanced solid tumors; Patients with FGFR mutation(including mutation, fusion, rearrangements ); Patients have measurable lesions; Patients are not available for targeted therapy or patients refuse to receive targeted therapy afer second-line treatment; Over 3 weeks after radiotherapy and the radiotherapy focus was not be measured; Age should be 18-25 years; Performance status should be 0-2; Life expectancy should be more than 12 weeks;

Exclusion Criteria:

Patients underwented major surgery or severe trauma within 4 weeks; Patients allergiced to experimental drugs; Patient ready to give birth or who is pregnant; Patients with brain metastases; Patients with chemotherapy contraindication; Patients could not tolerate chemotherapy; Patients have secondary primary tumor.

Related Conditions & MeSH terms

• Advanced Solid Tumor

Intervention

Drug:
• Anlotinib
Anlotinib

Locations

Country	Name	City	State
China	Shanghai Changzheng Hospital	Shanghai	Shanghai
China	Shanghai Changzheng Hospital	Shanghai	Shanghai
China	Shanghai Changzheng Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Changzheng Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate(ORR)	Evaluation of tumor burden based on RECIST criteria.	up to 36 months